340 related articles for article (PubMed ID: 2888532)
1. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
3. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
4. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
5. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
7. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
8. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.
Cass CE; Janowska-Wieczorek A; Lynch MA; Sheinin H; Hindenburg AA; Beck WT
Cancer Res; 1989 Nov; 49(21):5798-804. PubMed ID: 2790792
[TBL] [Abstract][Full Text] [Related]
9. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Politi PM; Arnold ST; Felsted RL; Sinha BK
Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771
[TBL] [Abstract][Full Text] [Related]
11. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.
Muller C; Goubin F; Ferrandis E; Cornil-Scharwtz I; Bailly JD; Bordier C; Bénard J; Sikic BI; Laurent G
Mol Pharmacol; 1995 Jan; 47(1):51-6. PubMed ID: 7838133
[TBL] [Abstract][Full Text] [Related]
12. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Qian XD; Beck WT
Cancer Res; 1990 Feb; 50(4):1132-7. PubMed ID: 1967551
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
14. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
15. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
Warren L; Jardillier JC; Ordentlich P
Cancer Res; 1991 Apr; 51(8):1996-2001. PubMed ID: 1672622
[TBL] [Abstract][Full Text] [Related]
16. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
Danks MK; Yalowich JC; Beck WT
Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
[TBL] [Abstract][Full Text] [Related]
17. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.
Yusa K; Tsuruo T
Cancer Res; 1989 Sep; 49(18):5002-6. PubMed ID: 2569930
[TBL] [Abstract][Full Text] [Related]
18. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
Zamora JM; Pearce HL; Beck WT
Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
[TBL] [Abstract][Full Text] [Related]
19. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
20. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
Colin M; Madoulet C; Baccard N; Arsac F; Jardillier JC
Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
